UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
| Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Date of Report:March 18, 2004
(Date of earliest event reported)
GTx, Inc.
| Delaware | 005-79588 | 62-1715807 | ||
| (State or other jurisdiction of | (Commission | (I.R.S. Employer | ||
| incorporation or organization) | File Number) | Identification No.) |
3 N. Dunlap Street
3rd Floor, Van Vleet Building
Memphis, Tennessee 38163
(901) 523-9700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
| ITEM 9. Regulation FD Disclosure. | ||||||||
| SIGNATURE | ||||||||
| EX-99.1 PRESS RELEASE | ||||||||
ITEM 9. Regulation FD Disclosure.
On March 17, 2004, GTx publicly announced that it had entered into a joint collaboration with Ortho Biotech Products L.P. for andarine and specified backup SARM compounds. The full text of the press release announcing the agreement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GTx, Inc. | ||||
| Date: March 18, 2004 | By: | /s/ Henry P. Doggrell | ||
| Name: | Henry P. Doggrell | |||
| Title: | General Counsel/Secretary | |||
